December 2010. Volume 6. Number 4

The inactivated influenza vaccine is less protective than the live attenuated virus vaccine after the fourth post vaccination month

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J. 2010;29:806-11.
Reviewers: Andrés de Llano JM1, Ochoa Sangrador C2.
1Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Jesús María Andrés de Llano. Email: jmandres@ono.com
Reception date: 10/10/2010
Acceptance date: 27/09/2010
Publication date: 28/10/2010

Abstract

Authors’ conclusions: the protection provided by the inactivated influenza vaccine in children declines by four to eight months postvaccination. For matched strains, data suggest that the relative efficacy of the live attenuated vaccine versus the inactivated vaccine in young children increases over time.  Relative efficacy against mismatched strains was similar over time. Further research is needed to confirm these findings and to characterize the duration of protection provided by inactivated vaccine in children.

Reviewers’ commentary: it seems that the inactivated virus vaccine produces less protection than the attenuated virus vaccine, especially after the fourth month of vaccination. New studies are needed to know the type of vaccine more suitable for use in children, considering its effectiveness, safety and cost-effectiveness.

How to cite this article

Andrés de Llano JM, Ochoa Sangrador C. La vacuna antigripal de virus inactivados protege menos que la de virus vivos atenuados a partir del cuarto mes postvacunación. Evid Pediatr. 2010;6:83.

AVC | Critically appraised articles

Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J. 2010;29:806-11.
Reviewers: Andrés de Llano JM1, Ochoa Sangrador C2.
1Servicio de Pediatría. Hospital General del Río Carrión. Palencia. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Jesús María Andrés de Llano. Email: jmandres@ono.com
Reception date: 10/10/2010
Acceptance date: 27/09/2010
Publication date: 28/10/2010

How to cite this article

Andrés de Llano JM, Ochoa Sangrador C. La vacuna antigripal de virus inactivados protege menos que la de virus vivos atenuados a partir del cuarto mes postvacunación. Evid Pediatr. 2010;6:83.

References

  1. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25:870-9.
  2. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685-96.
  3. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860-9.
  4. Comité Asesor de Vacunas de la Asociación Española de Pediatría. Recomendaciones para la campaña 2010-2011. Vacunación en la infancia y adolescencia frente a la gripe estacional [en línea][consultado: 1-X-2010]. Disponible en: http://www.vacunasaep.org/pdf/2010/gripe_2010-2011.pdf.
  5. Centers for Disease Control and Prevention. Seasonal flu. [en línea][consultado: 1-X-2010]. Disponible en: http://www.cdc.gov/flu/.
  6. Girard MP, Katz J, Pervikov Y, Palkonyay L, Kieny MP. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine. 2010;28:6811-20.

28/10/2010

Linked Comment